pyrazines has been researched along with Hodgkin Disease in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (52.38) | 29.6817 |
| 2010's | 9 (42.86) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, H; Goda, S; Hiraoka, N; Matsumoto, Y; Matsuyama, A; Omura, A; Ono, S; Shiotsu, S; Suga, Y; Sugitani, M; Takumi, C; Tanaka, S; Tsuji, T; Yuba, T | 1 |
| Aldinucci, D; Borghese, C; Carbone, A; Casagrande, N; Celegato, M; Colombatti, A | 1 |
| Agrawal, N; Buxton, A; Chen, L; Cole, PD; De Alarcon, PA; Drachtman, RA; Guillerman, RP; Hogan, SM; Horton, TM; Howard, SC; Liu, H; López-Terrada, D; McCarten, K; Mrazek, MD; Schwartz, CL; Sheehan, AM; Trippet, TM; Voss, S; Wu, MF | 1 |
| Careddu, G; Carlo-Stella, C; Castagna, L; Locatelli, SL; Santoro, A; Stirparo, GG | 1 |
| Ding, L; Duan, LN; Liu, J; Wang, HX; Wang, ZD; Xue, M; Yan, HM; Zhu, L | 1 |
| Besterman, J; Brady, H; Buglio, D; Heise, C; Khaskhely, NM; MacBeth, K; Mamidipudi, V; Martell, RE; Younes, A | 1 |
| Anderlini, P; Fanale, M; Fayad, L; Horowitz, S; Ji, Y; Kwak, LW; Liboon, MJ; Nunez, C; Popat, U; Pro, B; Samaniego, F; Younes, A | 1 |
| Bollard, CM; Buglio, D; Derenzini, E; Illés, A; Ji, Y; Jóna, A; Khaskhely, N; Medeiros, LJ; Shafer, JA; Younes, A | 1 |
| Ramchandren, R | 1 |
| Miyata, Y; Mizuno, H; Nakao, N; Nakayama, T; Naoe, T; Nishiwaki, S; Saito, S; Takeshita, K | 1 |
| Chim, CS; Choi, PT; Lee, WK | 1 |
| Schenkein, D | 1 |
| Aggarwal, BB; Bharti, A; Georgakis, GV; Li, Y; McConkey, D; Younes, A; Zheng, B | 1 |
| Böll, B; Borchmann, P; Engert, A; Hansen, H; Heuck, F; Pogge von Strandmann, E; Reiners, K; Rothe, A | 1 |
| Fayad, L; Pro, B; Younes, A | 1 |
| Deggerich, A; Haubert, D; Kashkar, H; Krönke, M; Pongratz, C; Seeger, JM; Wiegmann, K; Yazdanpanah, B | 1 |
| Borchmann, P; Engert, A; Keller, U; Naumann, R; Rummel, M; Sezer, O; Trelle, S | 1 |
| Bartlett, NL; Blum, KA; Canellos, GP; Cheson, BD; Johnson, JL; Niedzwiecki, D | 1 |
| Hsi, ED; Kung, J; Peng, X; Qiu, W; Yegappan, M; Yen-Lieberman, B; Zhao, X | 1 |
| Barr, P; Fisher, R; Friedberg, J | 1 |
| Bernstein, SH; Fisher, RI; Friedberg, JW; Jordan, CT; Kelly, J; Liesveld, J; Marquis, D; Mendler, JH; Rich, L; Rossi, RM; Voci, S | 1 |
3 review(s) available for pyrazines and Hodgkin Disease
| Article | Year |
|---|---|
Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Brentuximab Vedotin; Drug Therapy; Everolimus; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Immunoconjugates; Immunotherapy; Lenalidomide; Protease Inhibitors; Pyrazines; Recurrence; Rituximab; Secondary Prevention; Sirolimus; Thalidomide | 2012 |
Proteasome inhibitors in the treatment of B-cell malignancies.
Topics: Acetylcysteine; Animals; Boronic Acids; Bortezomib; Cell Cycle Proteins; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzymes; Gene Expression Regulation; Hodgkin Disease; Humans; Leukemia, B-Cell; Leupeptins; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mice; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; Oncogene Proteins; Peptide Hydrolases; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Substrate Specificity; Transcription Factors; Treatment Outcome | 2002 |
The role of bortezomib in the treatment of lymphoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Mantle-Cell; Protease Inhibitors; Pyrazines | 2007 |
6 trial(s) available for pyrazines and Hodgkin Disease
| Article | Year |
|---|---|
A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Disease-Free Survival; Hodgkin Disease; Humans; Ifosfamide; Neoplasm Recurrence, Local; Pyrazines; Vinblastine; Vinorelbine; Young Adult | 2015 |
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disease-Free Survival; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Pyrazines; Recurrence; Treatment Outcome; Young Adult | 2011 |
Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Hodgkin Disease; Humans; Male; Middle Aged; Pyrazines; Recurrence; Stem Cell Transplantation; Treatment Outcome | 2006 |
Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hodgkin Disease; Humans; Male; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Treatment Failure | 2007 |
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.
Topics: Adult; Boronic Acids; Bortezomib; Disease Progression; Female; Hodgkin Disease; Humans; Male; Middle Aged; Pyrazines; Salvage Therapy; Survival Analysis; Treatment Failure | 2007 |
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Middle Aged; Proteasome Endopeptidase Complex; Pyrazines | 2008 |
12 other study(ies) available for pyrazines and Hodgkin Disease
| Article | Year |
|---|---|
Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report.
Topics: Adenosine Monophosphate; Adult; Alanine; Amides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Brentuximab Vedotin; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Dacarbazine; Disease Progression; Doxorubicin; Hodgkin Disease; Humans; Male; Pregnenediones; Pyrazines; Time Factors; Vinblastine | 2021 |
Bortezomib down-modulates the survival factor interferon regulatory factor 4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-associated fibroblasts.
Topics: Boronic Acids; Bortezomib; CD40 Ligand; Cell Adhesion; Cell Line, Tumor; Cell Survival; Down-Regulation; Enzyme Activation; Fibroblasts; Gene Expression Regulation, Neoplastic; Hodgkin Disease; Humans; Interferon Regulatory Factors; NF-kappa B; Pyrazines | 2014 |
Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Cell Death; Cell Line, Tumor; Down-Regulation; Enzyme Inhibitors; Gene Expression; Hodgkin Disease; Humans; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Necrosis; Phosphoinositide-3 Kinase Inhibitors; Pyrazines; Reactive Oxygen Species; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2016 |
Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Male; Positron-Emission Tomography; Prednisone; Pyrazines; Vinblastine; Vinorelbine | 2009 |
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cytokines; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Hodgkin Disease; Humans; NF-kappa B; Protease Inhibitors; Pyrazines; Pyrimidines; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Up-Regulation | 2010 |
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
Topics: Acetylation; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Biphenyl Compounds; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Hodgkin Disease; Humans; Indoles; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Nitrophenols; Piperazines; Protein Processing, Post-Translational; Pyrazines; Pyridines; Pyrroles; Sulfonamides; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Female; Hodgkin Disease; Humans; Mast Cells; Mice; Mice, Inbred C57BL; Mice, SCID; Pyrazines; Tumor Microenvironment | 2012 |
Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Combined Modality Therapy; Dacarbazine; Dexamethasone; Doxorubicin; Epstein-Barr Virus Infections; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Salvage Therapy; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Vinblastine; Vincristine | 2013 |
Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
Topics: Antibodies, Monoclonal; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Carrier Proteins; Caspases; CD40 Antigens; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Survival; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Hodgkin Disease; Humans; I-kappa B Proteins; Ki-1 Antigen; Membrane Glycoproteins; Multienzyme Complexes; Mutation; NF-kappa B; NF-KappaB Inhibitor alpha; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2004 |
The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis.
Topics: Animals; Antibodies, Monoclonal; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Cytotoxicity, Immunologic; Disease Models, Animal; Drug Synergism; Hodgkin Disease; Humans; Intracellular Signaling Peptides and Proteins; Ki-1 Antigen; Mice; NF-kappa B; Pyrazines; Signal Transduction; Xenograft Model Antitumor Assays | 2005 |
NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs.
Topics: Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Hodgkin Disease; Humans; Jurkat Cells; Neoplasm Proteins; NF-kappa B; Pyrazines; Reed-Sternberg Cells; X-Linked Inhibitor of Apoptosis Protein | 2007 |
Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Gene Expression; Gene Expression Profiling; Hodgkin Disease; Humans; Immunohistochemistry; Oligonucleotide Array Sequence Analysis; Pyrazines; Reed-Sternberg Cells; Reverse Transcriptase Polymerase Chain Reaction; Tissue Array Analysis; TNF-Related Apoptosis-Inducing Ligand | 2008 |